A genetically immortalized human stem cell line: A promising new tool for Alzheimer’s disease therapy

Nicha Puangmalai, Alyma Somani, Wipawan Thangnipon, Clive Ballard, Martin Broadstock

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Amyloid-β peptides and hyper-phosphorylated tau are the main pathological hallmarks of Alzheimer’s disease (AD). Given the recent failure of several large-scale clinical trials and the lack of disease-modifying pharmacological treatments, there is an urgent need to develop alternative therapies. A clinical grade human CTX0E03 neural stem cell line has recently passed phase I trials in people with stroke. However, this cell line has not been investigated in other neurodegenerative disorders. This study investigates the survival of CTX0E03 cells under conditions based on the underlying AD pathology. Cell viability assays showed a concentration dependence of this cell line to the toxic effects of Aβ1-42, but not Aβ1-40, and okadaic acid, a phosphatase 2A inhibitor. Notably, CTX0E03 cell line displayed toxicity at concentrations significantly higher than both rat neural stem cells and those previously reported for primary cultures. These results suggest CTX0E03 cells could be developed for clinical trials in AD patients.

Original languageEnglish (US)
Pages (from-to)1135-1144
Number of pages10
JournalEXCLI Journal
Volume14
DOIs
StatePublished - Oct 21 2015
Externally publishedYes

Fingerprint

Alzheimer disease
stem cells
Alzheimer Disease
Stem Cells
cell lines
Cell Line
therapeutics
Neural Stem Cells
cell viability
clinical trials
Cell Survival
Clinical Trials
okadaic acid
Okadaic Acid
alternative medicine
Poisons
neurodegenerative diseases
amyloid
Therapeutics
Complementary Therapies

Keywords

  • Alzheimer’s disease
  • Cell viability
  • CTX0E03 cell line
  • Neural stem cell
  • Okadaic acid
  • Oligomeric amyloid-β

ASJC Scopus subject areas

  • Molecular Medicine
  • Animal Science and Zoology
  • Pharmacology
  • Drug Discovery

Cite this

A genetically immortalized human stem cell line : A promising new tool for Alzheimer’s disease therapy. / Puangmalai, Nicha; Somani, Alyma; Thangnipon, Wipawan; Ballard, Clive; Broadstock, Martin.

In: EXCLI Journal, Vol. 14, 21.10.2015, p. 1135-1144.

Research output: Contribution to journalArticle

Puangmalai, Nicha ; Somani, Alyma ; Thangnipon, Wipawan ; Ballard, Clive ; Broadstock, Martin. / A genetically immortalized human stem cell line : A promising new tool for Alzheimer’s disease therapy. In: EXCLI Journal. 2015 ; Vol. 14. pp. 1135-1144.
@article{ea90f5fdbe14426f887422c0a3d5a413,
title = "A genetically immortalized human stem cell line: A promising new tool for Alzheimer’s disease therapy",
abstract = "Amyloid-β peptides and hyper-phosphorylated tau are the main pathological hallmarks of Alzheimer’s disease (AD). Given the recent failure of several large-scale clinical trials and the lack of disease-modifying pharmacological treatments, there is an urgent need to develop alternative therapies. A clinical grade human CTX0E03 neural stem cell line has recently passed phase I trials in people with stroke. However, this cell line has not been investigated in other neurodegenerative disorders. This study investigates the survival of CTX0E03 cells under conditions based on the underlying AD pathology. Cell viability assays showed a concentration dependence of this cell line to the toxic effects of Aβ1-42, but not Aβ1-40, and okadaic acid, a phosphatase 2A inhibitor. Notably, CTX0E03 cell line displayed toxicity at concentrations significantly higher than both rat neural stem cells and those previously reported for primary cultures. These results suggest CTX0E03 cells could be developed for clinical trials in AD patients.",
keywords = "Alzheimer’s disease, Cell viability, CTX0E03 cell line, Neural stem cell, Okadaic acid, Oligomeric amyloid-β",
author = "Nicha Puangmalai and Alyma Somani and Wipawan Thangnipon and Clive Ballard and Martin Broadstock",
year = "2015",
month = "10",
day = "21",
doi = "10.17179/excli2015-560",
language = "English (US)",
volume = "14",
pages = "1135--1144",
journal = "EXCLI Journal",
issn = "1611-2156",
publisher = "University of Mainz",

}

TY - JOUR

T1 - A genetically immortalized human stem cell line

T2 - A promising new tool for Alzheimer’s disease therapy

AU - Puangmalai, Nicha

AU - Somani, Alyma

AU - Thangnipon, Wipawan

AU - Ballard, Clive

AU - Broadstock, Martin

PY - 2015/10/21

Y1 - 2015/10/21

N2 - Amyloid-β peptides and hyper-phosphorylated tau are the main pathological hallmarks of Alzheimer’s disease (AD). Given the recent failure of several large-scale clinical trials and the lack of disease-modifying pharmacological treatments, there is an urgent need to develop alternative therapies. A clinical grade human CTX0E03 neural stem cell line has recently passed phase I trials in people with stroke. However, this cell line has not been investigated in other neurodegenerative disorders. This study investigates the survival of CTX0E03 cells under conditions based on the underlying AD pathology. Cell viability assays showed a concentration dependence of this cell line to the toxic effects of Aβ1-42, but not Aβ1-40, and okadaic acid, a phosphatase 2A inhibitor. Notably, CTX0E03 cell line displayed toxicity at concentrations significantly higher than both rat neural stem cells and those previously reported for primary cultures. These results suggest CTX0E03 cells could be developed for clinical trials in AD patients.

AB - Amyloid-β peptides and hyper-phosphorylated tau are the main pathological hallmarks of Alzheimer’s disease (AD). Given the recent failure of several large-scale clinical trials and the lack of disease-modifying pharmacological treatments, there is an urgent need to develop alternative therapies. A clinical grade human CTX0E03 neural stem cell line has recently passed phase I trials in people with stroke. However, this cell line has not been investigated in other neurodegenerative disorders. This study investigates the survival of CTX0E03 cells under conditions based on the underlying AD pathology. Cell viability assays showed a concentration dependence of this cell line to the toxic effects of Aβ1-42, but not Aβ1-40, and okadaic acid, a phosphatase 2A inhibitor. Notably, CTX0E03 cell line displayed toxicity at concentrations significantly higher than both rat neural stem cells and those previously reported for primary cultures. These results suggest CTX0E03 cells could be developed for clinical trials in AD patients.

KW - Alzheimer’s disease

KW - Cell viability

KW - CTX0E03 cell line

KW - Neural stem cell

KW - Okadaic acid

KW - Oligomeric amyloid-β

UR - http://www.scopus.com/inward/record.url?scp=84946061251&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946061251&partnerID=8YFLogxK

U2 - 10.17179/excli2015-560

DO - 10.17179/excli2015-560

M3 - Article

AN - SCOPUS:84946061251

VL - 14

SP - 1135

EP - 1144

JO - EXCLI Journal

JF - EXCLI Journal

SN - 1611-2156

ER -